Review
Copyright ©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 746-766
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.746
Table 1 Clinical studies applying various hematopoietic stem cell mobilization chemotherapy + granulocyte colony-stimulating factor protocols in patients with relapsed/refractory germ cell tumors
Ref.
Number of patients
Successful mobilization
Mobilization regimen
Fruehauf et al[149] 1995 (prospective analysis)15Median BM 31.49 × 106/kg PB 0.46 × 106/kg 100%Cisplatin 100 mg/m2 etoposide 75 mg/m2 ifosfamide 2 g/m2 + G-CSF
Tada et al[150] 1999 (retrospective analysis)62.5 × 108/kg 100%Cisplatin 200 mg/m2 ifosfamide 4 g/m2 etoposide 100 mg/m2 d1-d3 + G-CSF
Rodenhuis et al[151] 1999 (multicenter prospective phase II)3510.3 × 106/kg 100%Cisplatin 200 mg/m2 ifosfamide 4 g/m2 etoposide 100 mg/m2 d1-d3 + G-CSF
Lotz et al[152] 2005 TAXIF 2005 (retrospective analysis)459 × 106/kg (for 3 HDCT) 100%Epirubicin 120 mg/m2 - paclitaxel 200 mg/m2 + G-CSF
Argawal et al[102] 2009 (retrospective analysis)373-6 × 106/kg 100%ifosfamide 2-4.5 g/m2 + G-CSF
Feldman et al[153] 2010 (prospective phase I/II)107> 2 × 106/kg 100%TI: paclitaxel 200 mg/m2 d1 ifosfamide 2 g/m2 d1-d3 + G-CSF
Haugnes et al[154] 2012 (prospective analysis)882> 2 × 106/kg 100%BEP-ifosfamide + G-CSF
Mohr et al[155] 2012 (retrospective analysis)44> 4 × 106/kg 100%PEI (cisplatin, etoposide, ifosfamide) + G-CSF Plerixafor in poor mobilizers
Necchi et al[156] 2015 (review)42> 2 × 106/kg 100%BEP + G-CSF
Moeung et al[157] 2017 (pharmacokinetic phase II study)89> 9 × 106/kg (for 3 HDCT) (1-2 cycles) 100%TI: paclitaxel, ifosfamide + G-CSF
Hamid et al[106] 2018 (retrospective analysis)3510/35 plerixafor + G-CSF 95%TI: paclitaxel, ifosfamide or TIP
Argawal et al[158] 2019 (retrospective analysis)321172 allogeneic 95% 149 autologous 73% 77/149 without plerixafor → 64% success 72/149 with plerixafor → 82% successG-CSF ± Plerixafor
Yildiz et al[159] 2020 (retrospective analysis)50> 2 × 106/kg 100%TIP + G-CSF
Ussowicz et al[160] 2020 (retrospective analysis)18 (children)Median: 4.56 × 106/kg 100%Cyclophosphamide 4 g/m2 + G-CSF
Chevreau et al[161] 2020 (multicenter prospective phase II)89> 9 × 106/kg (for 3 HDCT) 100%TI: paclitaxel, ifosfamide + G-CSF
G-CSF: Granulocyte colony-stimulating factor; HDCT: High-dose chemotherapy; TIP: Paclitaxel (Taxol)-ifosfamide-cisplatin.